Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
List view / Grid view
3 August 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced an agreement with Servier & its partner XOMA Corporation...
25 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1
23 July 2012 | By Boehringer Ingelheim
FX125L is a small molecule...
16 July 2012 | By Boehringer Ingelheim
This year's Boehringer Ingelheim FENS Award was granted to Ilka Diester...
10 July 2012 | By Boehringer Ingelheim
Boehringer Ingelheim is concentrating on new business models...
9 July 2012 | By Boehringer Ingelheim
"We are very pleased to sponsor the joint research programs..."
5 July 2012 | By Boehringer Ingelheim
Joachim Hasenmaier to lead new Board Division Consumer Healthcare and Animal Health...
28 June 2012 | By Boehringer Ingelheim
Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…
20 June 2012 | By Boehringer Ingelheim
The design of the RE-ALIGN study published...
18 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim BioXcellence: Distinctive brand for the biopharmaceutical contract manufacturing business...
18 June 2012 | By Boehringer Ingelheim
Pradaxa® is associated with a substantially shorter interruption of oral anticoagulation therapy...
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
6 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has updated the US prescribing information for Pradaxa®...
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
4 June 2012 | By Boehringer Ingelheim
LUX-Lung 3 results highlighted at the official ASCO Press Conference...